A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma
An Open-Label Phase ½ Study of INCB039110 in Combination With Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma